Respiratory Syncytial Virus (RSV) Diagnostics Market Report 2026

The respiratory syncytial virus (rsv) diagnostics market size has grown rapidly in recent years. It will grow from $1.12 billion in 2025 to $1.24 billion in 2026 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to rising incidence of pediatric respiratory infections, increasing hospitalization rates among elderly populations, wider availability of immunoassay technologies, expansion of diagnostic laboratory networks, increased clinical awareness of rsv.

The respiratory syncytial virus (rsv) diagnostics market size is expected to see rapid growth in the next few years. It will grow to $1.84 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing demand for early and accurate respiratory diagnosis, growing adoption of home testing kits, rising investments in molecular diagnostics, expansion of multiplex testing adoption, increasing focus on pediatric preventive care. Major trends in the forecast period include increasing adoption of rapid point-of-care rsv tests, rising use of molecular diagnostic assays, growing integration of multiplex respiratory panels, expansion of home-based rsv testing solutions, enhanced focus on early infant diagnosis.

The increasing prevalence of respiratory diseases is anticipated to drive the growth of the respiratory syncytial virus (RSV) diagnostics market in the coming years. Respiratory diseases comprise a range of conditions that affect the airways and lungs, disrupting normal breathing and oxygen exchange, and include disorders such as asthma, chronic obstructive pulmonary disease (COPD), pneumonia, and various respiratory infections. The growing burden of respiratory diseases is attributed to factors such as rising air pollution, smoking, climate change, rapid urbanization, and the increasing incidence of infections and chronic respiratory conditions like asthma and COPD. RSV diagnostics play a critical role in respiratory disease management by enabling accurate and timely detection of RSV infections, supporting appropriate treatment decisions, effective disease management, and the prevention of serious complications, particularly among high-risk populations. For example, in June 2025, according to the Office for Health Improvement and Disparities (OHID), a UK-based government department, emergency admissions for respiratory diseases in England rose by 7% from the financial year ending 2023 to the financial year ending 2024. Therefore, the growing prevalence of respiratory diseases is fueling the expansion of the respiratory syncytial virus (RSV) diagnostics market.

Major companies operating in the respiratory syncytial virus (RSV) diagnostics market are concentrating on the development of innovative solutions, such as respiratory virus combination testing, to deliver accurate and efficient diagnostic outcomes. Respiratory virus combination testing is a diagnostic approach that allows simultaneous detection of multiple respiratory viruses, including influenza, RSV, and others, from a single patient sample, facilitating faster and more comprehensive identification of viral infections. For instance, in January 2023, Sonora Quest Laboratories, a US-based clinical laboratory testing company, introduced a combined COVID-19, RSV, and influenza diagnostic test. This molecular diagnostic assay performs qualitative, multi-target analysis using a single sample to detect COVID-19, respiratory syncytial virus, and influenza. By integrating the detection of all three viruses into one test, the solution streamlines testing workflows, reduces the need for multiple sample collections, and enables quicker clinical decision-making, which can improve patient outcomes and help limit viral transmission.

In November 2023, Medix Biochemica, a Finland-based biotechnology company, acquired ViroStat LLC for an undisclosed amount. Through this acquisition, Medix Biochemica aims to broaden its infectious disease diagnostics portfolio by leveraging ViroStat’s expertise in developing diagnostic solutions, including those focused on respiratory syncytial virus (RSV). ViroStat LLC is a US-based company that provides a variety of diagnostic products, such as monoclonal antibodies and antigen detection kits for RSV testing.

Major companies operating in the respiratory syncytial virus (rsv) diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Merck KGaA, Becton, Dickinson, and Company, Quest Diagnostics Incorporated, Hologic Inc., BIOMÉRIEUX SA, QuidelOrtho Corporation, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Acon Laboratories Inc., Cepheid Inc., Meridian Bioscience Inc., Seegene Inc., LumiraDx Ltd., Sekisui Diagnostics Ltd., Boditech Med Inc., Trinity Biotech plc, R-Biopharm AG, GeneTex Inc., Creative Diagnostics, Certest Biotec S.L., Clarity Diagnostics LLC, Genes 2Me LLP, Coris BioConcept S.A.

North America was the largest region in the respiratory syncytial virus (RSV) diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory syncytial virus (rsv) diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the respiratory syncytial virus (rsv) diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the RSV diagnostics market by increasing the cost of imported PCR analyzers, immunoassay instruments, reagents, enzymes, and sample collection consumables used across hospitals and diagnostic laboratories. North America and Europe are most affected due to reliance on imported diagnostic components, while Asia-Pacific faces pricing pressure on exported test kits and reagents. These tariffs are increasing per-test costs and slowing procurement cycles for smaller laboratories. However, they are also encouraging domestic reagent manufacturing, regional production of diagnostic kits, and localized supply chain development, supporting long-term diagnostic self-sufficiency.

The respiratory syncytial virus (rsv) diagnostics market research report is one of a series of new reports that provides respiratory syncytial virus (rsv) diagnostics market statistics, including respiratory syncytial virus (rsv) diagnostics industry global market size, regional shares, competitors with a respiratory syncytial virus (rsv) diagnostics market share, detailed respiratory syncytial virus (rsv) diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory syncytial virus (rsv) diagnostics industry. This respiratory syncytial virus (rsv) diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Respiratory syncytial virus (RSV) diagnostics refers to the testing methods and procedures used to detect the presence of RSV in patients, typically using respiratory samples such as nasal swabs or throat swabs. These diagnostics help identify RSV infections, which can lead to respiratory illness in infants, young children, and elderly individuals, and support appropriate treatment and management decisions.

The main types of respiratory syncytial virus (RSV) diagnostic products include kits and assays, instruments, reagents, and others. Kits and assays are prepackaged sets of reagents, materials, and instructions designed for specific diagnostic tests. These products utilize technologies such as molecular diagnostics, immunoassays, rapid antigen detection tests, and others, and work with various sample types including nasal swabs, throat swabs, and bronchoalveolar lavage samples. They are used by hospitals, diagnostic laboratories, home care settings, and other end users.

The respiratory syncytial virus (RSV) diagnostics market consists of revenues earned by entities by providing services such as diagnostic consultation, research and development support, training and technical support. The market value includes the value of related goods sold by the service provider or included within the service offering. The respiratory syncytial virus (RSV) diagnostics market also includes sales of immunofluorescence test kits, multiplex panels, sample collection devices and automated testing instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.